Tralokinumab

Tralokinumab is a human monoclonal antibody developed for the treatment of inflammatory skin conditions, primarily atopic dermatitis (also known as eczema). It targets interleukin-13 (IL-13), a key cytokine involved in the pathogenesis of atopic dermatitis and other allergic diseases. By binding to IL-13, tralokinumab helps reduce inflammation and skin barrier dysfunction, which are central features of the condition.

The drug was initially studied by AstraZeneca under the code name **AZD2767** before being acquired by Johnson & Johnson’s Janssen Pharmaceuticals. Clinical trials have shown promising results in reducing disease severity, itching, and improving quality of life in patients with moderate to severe atopic dermatitis who did not respond adequately to topical treatments. It is administered via subcutaneous injection, typically every two weeks or once a month, depending on the dosing regimen.

Tralokinumab was approved by the U.S. Food and Drug Administration (FDA) in 2021 for adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy or phototherapy. It is also under investigation for other inflammatory conditions, including asthma and chronic rhinosinusitis with nasal polyps, though its use in these areas remains experimental.

Common side effects of tralokinumab include injection-site reactions, headache, and upper respiratory infections. More serious adverse effects, such as increased risk of infections or allergic reactions, are rare but monitored closely in clinical settings. The drug is not recommended for use in patients with active or severe infections.

Research continues to explore tralokinumab’s potential in expanding its therapeutic applications, particularly in conditions where IL-13 plays a significant role. Its mechanism of action makes it a targeted therapy, offering an alternative to broader immunosuppressants used in managing chronic inflammatory diseases.